Our results revealed that Rab31 promotes tumor metastasis and cisplatin resistance in STAD through Twist1-mediated EMT, which suggests that Rab31/Stat3/MUC-1/Twist1 pathway is a promising therapeutic target to overcome resistance to cisplatin and metastasis in STAD. The gene discussed is MUC1; the disease is gastric adenocarcinoma.